Appointment to the Board

Premaitha Health PLC

Appointment to the Board

Manchester, UK - 28 October 2015 - Premaitha Health PLC (AIM: NIPT, "Premaitha" or the "Company"), developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT) confirms that Chief Medical Officer, Dr William Denman, will join the Board of Premaitha as an Executive Director on 1 November 2015.

Dr Denman has been working with Premaitha for over four years. This appointment will further strengthen the Board and is a continued part of the Company's commercialisation strategy.

Dr Denman has significant experience in the clinical aspects of device and diagnostic development having specialised in paediatric anaesthesia and medical device development at Massachusetts General Hospital. Previously, he was CMO with GE Healthcare with primary responsibility for all matters of patient safety in this multi-billion dollar business. He has also been responsible for strategic direction of medical affairs, clinical affairs and healthcare economics and outcomes across Covidien plc's medical device business. Dr Denman studied medicine at the University of Aberdeen.

David Evans, Chairman of Premaitha commented: "Over the last four years, we've developed a great partnership with William. He has helped build strong relationships between Premaitha and some of the key opinion leaders in NIPT, putting us at the forefront of this nascent sector. His impressive experience and track record will further strengthen our Board and management team as we continue to ramp-up our commercialisation strategy."

Further information pursuant to schedule 2(g) of the AIM Rules is set out below.

William Tzocor Denman IV, aged 52, holds, or has held in the last 5 years, the following directorships and partnerships:

Dr Denman holds 250,000 ordinary shares in the Company, representing 0.1 per cent. of the Company's issued share capital.

-Ends-

Notes to Editors

About Premaitha Health

Premaitha is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha's flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.

The IONA® test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha's clinical laboratory customers to perform the test in their own facilities. This supports Premaitha's strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.

Premaitha is listed on the London Stock Exchange (AIM). Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK. For further information please visit www.premaitha.com or email iona@premaitha.com.